Navigation Links
NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
Date:8/4/2011

or "placebo") did not.  Subjects receiving active treatment showed a 40% responder rate after 18 weeks of daily stimulation compared to a 15% responder rate in the placebo group.  A responder is defined as someone who experiences a greater than 50% reduction in seizures.  In addition to reducing seizures, eTNS™ also improved mood.  These results confirm and extend the findings of DeGiorgio's positive feasibility trial in epilepsy, reported in 2009 in the journal, Neurology.

At the same conference, DeGiorgio also revealed a potential mechanism of action for the eTNS™ treatment of epilepsy.  Using Positron Emission Tomography (PET), significant decreases in regional cerebral blood flow were detected in several regions of the cerebral cortex, which is where seizures originate.

NeuroSigma is currently developing its next generation eTNS™ system and in 2012 anticipates filing a CE Mark application for approval to commence marketing its new eTNS™ system for the treatment of epilepsy in Europe.

In addition, in 2012, the company anticipates filing an IDE for an upcoming multi-center Phase III pivotal trial in the United States.  Neither NeuroSigma nor UCLA are currently enrolling subjects for eTNS™ epilepsy trials.

Future updates regarding clinical trials, including potential enrollment details, and study results will be posted on NeuroSigma's website (www.neurosigma.com).

CAUTION: The eTNS™ system is an investigational device and at this time is limited by United States law for investigational use only in approved research protocols.  NeuroSigma does not recommend the off-label use of nerve or muscle electrical stimulation units for any purpose not approved by the FDA because of the potential risk of injury or death.  

About NeuroSigma, Inc.

NeuroSigma is a Los Angeles-based medical techn
'/>"/>

SOURCE NeuroSigma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeuroSigma, Inc. Retains CCG Investor Relations
2. NSVascular, Inc., a NeuroSigma Subsidiary, Signs an Exclusive License Covering UCLAs Thin-Film Nitinol (TFN) Stent Technology for Endovascular Applications
3. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
4. Roche responds to announcement of IDEAL hepatitis C trial results
5. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
6. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
7. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
8. EPSScentral Responds to Pandemic Alert
9. Endologix Responds to Alleged Patent Infringement
10. U.S. Kidney Dialysis Community Responds to Haitis Emergency Plea for Life-Saving Dialysis Care
11. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... CARLSBAD, Calif. , May 4, 2015  Isis ... an exclusive license agreement with Bayer HealthCare (Bayer) to ... of thrombosis. Under the terms of the agreement, Isis ... near-term payments, including an immediate $100 million up-front payment ... program following a Phase 2 study in patients with ...
(Date:5/4/2015)... NEW YORK , May 4, 2015  FireflySci Inc., the newest member of the ... months after launch, they have turned the cuvette industry on its head by offering scientists amazing ... http://photos.prnewswire.com/prnh/20150501/213243LOGO Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
(Date:5/4/2015)... 2015 Intarcia Therapeutics, Inc. ... into the newly created role of Chief ... pharmaceutical executive with world-class experience – most recently ... service at industry leaders such as Pfizer and ... range of therapeutic areas, including: cardiovascular, metabolic, oncology, ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4
(Date:5/4/2015)... In response to the proposed mammography ... (USPSTF), Strategic Radiology® (SR®) fully aligns itself with ... Gynecologists (ACOG), the American College Of Surgeons, Susan ... (ACS), American College of Radiology (ACR), and Society ... screening mammography for women beginning at age 40 ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 For partners ... brand new lubricant -- Astroglide TTC™ (Trying to ... motility and alter pH levels, Astroglide TTC™ is specially ... , According to the Centers for Disease Control, an ... trouble getting pregnant or sustaining a pregnancy, and over ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 Fast ... Eric Gladen’s documentary Trace Amounts, and Allison Folmar, JD, ... autism conference held internationally. , On Sunday, May 24, ... recovery from autism possible?" Are you interested in Ryan ... In There: winning our war against autism was ...
(Date:5/4/2015)... 2015 “St. Louis has long represented ... the West,” so it is the perfect place for ... Dr. Ben Litalien, Chief Development Officer for Zerorez. ... and will provide veterans with a $10,000 discount on ... to have a number of Military Veterans in its ...
(Date:5/3/2015)... 2015 AvePoint, the ... and devices, today announced it is a Platinum ... (IAPP) Asia Privacy Forum, taking place May 5-6, ... event, AvePoint will showcase its compliance, risk, and ... , Visit AvePoint for New Solutions , ...
Breaking Medicine News(10 mins):Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4
... an Increase in the, Number of Patients Treated for Low ... Surveyed MCOs Will Not Add Novel HDL Drugs to Their ... According to a New Report from Decision Resources, ... leading research and advisory firms for pharmaceutical and,healthcare issues, finds ...
... are concerned about access to care for seniors, and ... Medicare patients,according to a new public poll released today ... payments to physicians will be cut,10.6 percent, and over ... 40,percent while medical practice costs increase 20 percent., ...
... PITTSBURGH, March 19 To develop new strategies to ... of the worlds population and kills almost two million ... Vaccine Research has received an $11.4 million grant from ... enable Pitt researchers to use new imaging technologies to ...
... 19 Goosie, LLC announced today,that they will ... throughout the month of April with a series ... autistic children with special,discounts. Goosie is the market ... Cards are created online at http://www.goosiecards.com ...
... UMDNJ has received a grant for the UMDNJ-University Hospital ... Federation (IDF) BRIDGES program to tailor interventions to improve ... 2 diabetes. , The academic teaching hospital provides ... found that many of its patients never connect to ...
... follow a genetic program independent of developing tissue , , ... concept of how the brain,s blood supply develops is ... researchers. , In experiments with mice, the researchers found ... their own agenda beginning early in fetal development. They ...
Cached Medicine News:Health News:One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines 2Health News:One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines 3Health News:New Poll Shows Public Worried About Medicare Cuts Impact on Seniors, Boomers - Wants Congress To Act 2Health News:Stopping a deadly killer 2Health News:Goosie Cards to Support Autism Awareness Month With Special Discount Program 2Health News:International Diabetes Federation gives grant to UMDNJ-University Hospital in Newark 2Health News:International Diabetes Federation gives grant to UMDNJ-University Hospital in Newark 3Health News:Brain Blood Vessels Grow With Their Own Agenda 2
The Olympus full range of laparoscopes includes a range of diameters and directions of view -12 mm HDTV compatible model as well as a choice of 10 mm, 5 mm full screen and 3 mm....
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
Compact, economical Bactron II anaerobic environment system with air lock, workspace and a 200 plate capacity incubator delivers optimum productivity in a compact space....
This chamber is designed to provide a large workspace and gloveless dexterity in closed environment industrial, research and development, quality control packaging applications. Atmospheres of nitrog...
Medicine Products: